In a study by Alghamdi et al. 30, in 2022, the KRAS mutation shown in 50% of CRC patients has a significant association with the right-sided tumor and with peritoneal metastases, but other clinicopathological characteristics show no significant association. The gene discussed is KRAS; the disease is neoplasm.